SREBF2 and atherosclerosis: Moreover, it inhibited the hepatic mRNA expression of the liver X receptor (LXR), the low density lipoprotein receptor (LDLR), sterol regulatory element-binding protein 2 (SREBP-2), and β-hydroxy β-methylglutaryl-CoA (HMG-CoA) in vivo, which could suggest the protective properties against hepatic steatosis and atherosclerosis.